Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Biosion
Mingjiu Chen on LinkedIn: Biosion Presents Discovery and Development ...
Biosion Announces Exclusive, Global License Agreement with Aclaris ...
#biosion #immunogen #adc #antibody #collaboration #biotech | Biosion
#fdaapproval #medicalinnovation #biotech | Biosion
Biosion to Present Three Posters at the 2024 AACR Meeting | Biosion
Biosion will be attending the BIO-Europe Spring virtually March 28-30 ...
Biosion on LinkedIn: Biosion’s Partner OBI Pharma Announces FDA ...
Biosion monoclonal antibody therapies to be featured at the American ...
Today we are pleased to announce that Biosion has successfully opened ...
Biosion Doses First Patient In Phase 1 Trial Of Novel Anti SIRPα ...
Biosion gets FDA approval for BSI-082 | Biointron posted on the topic ...
#pipeline #pharma #collaboration #biotech #oncology #immunology | Biosion
Biosion shares Anti-CD40 Agonistic Antibody discovery and development ...
Biosion | LinkedIn
SynTracer® High-Throughput Endocytosis Platform - Biosion
We are pleased to announce that Biosion will participate in the 2023 ...
Biosion doses first patient in phase Ia/Ib BSI-082 trial for solid tumours
Biosion - 2026 Company Profile, Team, Funding & Competitors - Tracxn
Biosion 授權 Aclaris,推進免疫資產商業化 - 財報狗
Biosion and Aclaris Ink Global Licensing Deal for Novel Immunology Products
Biosion Announces Research Collaboration with ImmunoGen to Create Novel ...
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B ...
Biosion on LinkedIn: #oncology #immunology #bioeurope2022
Biosion Secures $40M Upfront in Licensing Deal with Aclaris ...
Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis
Yao-Yao Zhu - Head, Global Regulatory Affairs at Biosion | The Org
#pipeline #biosion #antibody | Biosion
Pipeline - Biosion
Andrea Hu - Biosion Inc., Head of Translational Medicine | LinkedIn
Rakesh Dixit - Advisor at Biosion | The Org
Biosion: Home
博奥信生物技术(南京)有限公司_百度百科
博奥信(BioSion)完成数千万元B+轮融资_创投之家
Happy to be at Bio-Europe this week and in early November at ChinaBio ...
#jpm2025 #biotech #oncology #antibody #biosion #i #bispecific #adc ...
博奥信
Congratulations to our RA/QA and clinical development teams! 🎉🎊🎈 ...
Biosion's BSI-082 Enters Phase 1 Trial for Advanced Solid Tumors | DC ...
#biochina #antibodyinnovation #globalization #biosion # ...
#bio2025 #biochina2025 #biotech #biochinaglobalforum #biosion # ...
BSI-082(BSI-082) - 药物靶点:SIRPα_在研适应症:局部晚期恶性实体瘤,转移性实体瘤,实体瘤_专利_临床_研发
Biosion, In Global For Global, antibody-drug conjugate, bosakitug TSLP ...
OBI-992 has been approved by US FDA for Orphan Drug Designation for the ...
#biochina2025 #biosioninc #globalforum #biotech #leadership #innovation ...
#biopharmaglobalization #newco #licensing #asiabio2025west #biosion ...
Biosion's New Drug BSI-082 Receives FDA Approval for Investigational ...
#antibodychina #antibody #antibodyinnovation #biotechfuture # ...
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head ...
PHASE 3, PHASE 3 Products, PHASE 3 Manufacturers, PHASE 3 Suppliers and ...
Science – Minapharm Pharmaceuticals
Global Biopharma Cross-border Summit 2023 — MSQ
HOME | biorizon.es
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer ...
Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc ...
Aclaris Therapeutics secures global rights to Biosion’s antibodies
NJ Bio, Inc. — Antibody Production
Research & Reagent Cell Lines
AIMS Lab | Department of Biological Sciences | University of Alaska ...
Addgene Blog: A Better Way to Share Science
We are pleased to serve as financial advisor and placement agent to ...
Queensland Biotherapeutics Pipeline - Australian Institute for ...
Aureka完成千万美元种子轮融资,高通量数字生物技术与AI结合颠覆大分子药物研发范式医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Biosion’s BSI-737 exerts strong antitumor activity | BioWorld
Biosion's anti-SIRPα antibody BSI-082 cleared to enter clinic | BioWorld
Biology PowerPoint Incl. presentation & education - Envato
Aclaris (ACRS) Advances Groundbreaking Therapies for Autoimmune ...
Biosion, Inc. (博奥信生物技术(南京)有限公司) - 药物管线_专利_临床试验_投融营收_最新药物:Bosakitug,BSI ...
CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 ...
Selecting the Right Platform for Your Antibody Discovery Project ...
Chu Zhang - Executive Director, Early Drug Development PPMO Head at ...
The bioseparation needs for tomorrow: Trends in Biotechnology
Single source provider of full-service therapeutic antibody development ...
TSLP inhibitor Market Insights, Patient pool and Competitive Landscape 2034
Pathology Newsletter
Laboratory Archives - Phase One Design
A New Workflow to Generate Monoclonal Antibodies against Microorganisms
博奥信完成B+轮融资,持续打造创新抗体开发平台,贯彻全球商业化战略医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Pipeline - Precision Biologics
Best Bio PPT Presentation Slide - Hierarchy Of Life
OBI Pharma announced FDA approval for a Phase 1/2 trial of its TROP2 ...
Figure 1 from Current Therapeutic Antibody Production and Process ...
Case Study: Standard Biocarbon Infographics — Foran Concepts
Pharmaceuticals | Free Full-Text | Experimental Nuclear Medicine Meets ...
Table 2 from What Does the Pipeline Promise about Upcoming Biosimilar ...
Making cancer curable: delivering on the promise of immunotherapy ...
Biosion, Inc. and Celldex present positive preclinical data at SITC 2021
Monoclonal antibodies cancer treatment | Monoclonal antibody ...
Membuat Bioenergi dari Kotoran Babi #bioenergi #kotoran #babi - YouTube
Therapeutic antibody discovery and optimization with a twist
#jpm2025 #biopharma #innovation #adc #bispecificantibodies #biologics # ...
Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to ...
Therapeutic Pipeline | Biolojic Design
BioCentury - Bispecifics for I&I: Bypassing combination complexity
Pathology Core Research Lab | Pathology Core Lab
The European AntibotABE Framework Program and Its Update: Development ...
Frontiers | How can we discover developable antibody-based biotherapeutics?
Home | High-Performance Computing in Europe
Biotechnology and Bioengineering: Vol 114, No 2